4DMT is a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology.

Pivot Bio, a sustainable agriculture company focused on microbial nitrogen, opened its Customer Success Center last week in the Iowa State University Research Park.

The multiyear collaboration and licensing pact, disclosed Tuesday morning, comes with $15 million upfront and up to $629 million in biobucks.

The program only requires a common 3D MRI scan, with no contrast injections, as well as cognitive test scores that are typically collected during a diagnostic workup.

ZymoChem will launch its first high-performance material and advance its first partnered product to commercial scale.

LIFT Ventures will be a vehicle for investing in innovative early-stage companies within the beauty wellness space.

The Phase 1 trial will be conducted by researchers from the National Cancer Institute as part of a Cooperative Research and Development Agreement. GigaGen anticipates trial initiation in 2024.

The awards will enable both companies to generate important proof-of-concept data that will help them attract seed investment to grow and develop their technologies and teams.

Promising data in adult patients supports advancement into pediatric patients. Data from this portion of the clinical program will inform a pivotal study.

Existing data on Carmot’s lead medicine “suggests a best-in-class potential to achieve and maintain weight loss with differentiated efficacy.”

Zotatifin is a sequence-selective small molecule inhibitor of the RNA helicase eIF4A. The drug is designed to inhibit the expression of a cancer-driving protein network.

Researchers at UCSF have mapped the microscopic world of autism spectrum disorder in unprecedented detail, pointing toward possible therapies for a subset of patients.

Randomized, placebo-controlled trial to assess 16-week treatment with CT-868 in participants with overweight or obesity with type 1 diabetes.

Delpor's drug/device combination risperidone implant (DLP-114) was well tolerated for up to 12 months.

GIGA-564 is a differentiated anti-CTLA-4 antibody with potential to enhance anti-tumor activity and mitigate immune-related toxicities associated with traditional CTLA-4 blockade.

Assembly Biosciences will get $100 million upfront in cash and stock in a 12-year research and development pact with Gilead Sciences.

The results are summarized in three poster presentations taking place at ObesityWeek® in Dallas, October 14-17, 2023.

Bolt was founded in 2009 to crack the code on growing artificial spider silk.

Mitokinin is developing the “PINK1” activator to correct mitochondrial dysfunction.